Trulieve Cannabis (TRUL) Stock Overview
Operates as a cannabis retailer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TRUL Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ST
stuart_roberts
Community ContributorUS$21.53FV • 64.4% undervalued intrinsic discount
5419.8%Revenue growth p.a.
6.2k
18
0
129
Trulieve Cannabis Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$13.13 |
| 52 Week High | CA$16.35 |
| 52 Week Low | CA$4.45 |
| Beta | 1.58 |
| 1 Month Change | 54.83% |
| 3 Month Change | 34.25% |
| 1 Year Change | 103.88% |
| 3 Year Change | 68.77% |
| 5 Year Change | -73.58% |
| Change since IPO | 31.56% |
Recent News & Updates
TRUL: Schedule III Shift And Repriced P E Multiple Will Drive Upside
Analysts raised their price target for Trulieve Cannabis to CA$15.26 from CA$14.95, citing updated assumptions based on higher modeled revenue growth, stronger profit margins, and a more moderate future P/E multiple. Analyst Commentary Street research on the broader equity market has included several cautious revisions and lower price targets, which can help frame how bearish analysts might approach a stock like Trulieve Cannabis.
TRUL: Higher Margin Profile And Rich Future P/E May Support Repricing
Analysts have lifted their fair value estimate for Trulieve Cannabis to CA$20.36 from CA$19.53, citing updated assumptions that reflect more conservative revenue growth, a higher profit margin profile, and a very large future P/E multiple that aligns with recent Street research patterns of recalibrating price targets while keeping core views intact. Analyst Commentary Street research across sectors shows a pattern of price target resets that keep long term theses largely intact, and this context helps frame how to read the updated fair value for Trulieve Cannabis.Recent updates
TRUL: Schedule III Shift And Repriced P E Multiple Will Drive Upside
Analysts raised their price target for Trulieve Cannabis to CA$15.26 from CA$14.95, citing updated assumptions based on higher modeled revenue growth, stronger profit margins, and a more moderate future P/E multiple. Analyst Commentary Street research on the broader equity market has included several cautious revisions and lower price targets, which can help frame how bearish analysts might approach a stock like Trulieve Cannabis.TRUL: Higher Margin Profile And Rich Future P/E May Support Repricing
Analysts have lifted their fair value estimate for Trulieve Cannabis to CA$20.36 from CA$19.53, citing updated assumptions that reflect more conservative revenue growth, a higher profit margin profile, and a very large future P/E multiple that aligns with recent Street research patterns of recalibrating price targets while keeping core views intact. Analyst Commentary Street research across sectors shows a pattern of price target resets that keep long term theses largely intact, and this context helps frame how to read the updated fair value for Trulieve Cannabis.TRUL: Schedule III Shift And Lower P E Multiple Will Drive Upside
Analysts have nudged their fair value price target for Trulieve Cannabis to CA$14.95, reflecting updated assumptions for slightly higher revenue growth, modestly improved profit margins, and a lower future P/E multiple in their models. Analyst Commentary While the latest fair value update suggests analysts see some improvement in Trulieve Cannabis' revenue and margin profile, there is still a clear undercurrent of caution in recent research across adjacent data and credit reporting names that can inform how you think about risk.TRUL: Schedule III Shift And Higher P E Assumptions Will Drive Future Upside
Analysts have slightly raised their fair value estimate for Trulieve Cannabis to about CA$14.95 from CA$14.69, reflecting updated assumptions around slower revenue growth, tighter profit margins and a much higher future P/E multiple that mirrors recent Street work, where price targets have been adjusted while views on long term earnings power and business mix continue to evolve. Analyst Commentary Street research around information services and data providers has recently highlighted how quickly sentiment can shift when investors question earnings durability, pricing power or the impact of new technology.TRUL: Rescheduling To Schedule III Will Shape Future Upside Potential
Analysts have trimmed their price target on Trulieve Cannabis by a small amount to reflect a slightly lower fair value estimate of CA$14.69. This incorporates updated assumptions that include modestly adjusted revenue growth, profit margin outlook and future P/E expectations.Some Confidence Is Lacking In Trulieve Cannabis Corp. (CSE:TRUL) As Shares Slide 30%
Feb 12
TRUL: Rescheduling To Schedule III Will Support Higher Future Earnings Multiples
Analysts have slightly raised their fair value estimate for Trulieve Cannabis to $19.53 from $19.06, citing updated assumptions around the discount rate, revenue growth, profit margins, and future P/E levels. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which would apply to companies such as Trulieve Cannabis that operate in the sector (Marijuana Herald).TRUL: Future Rescheduling And Tax Relief Prospects Will Shape Upside Potential
Analysts have trimmed their fair value estimate for Trulieve Cannabis by about $0.12 to roughly $14.78, reflecting updated assumptions around slightly higher revenue growth, a wider profit margin profile, and a lower future P/E multiple. Analyst Commentary Some bearish analysts are using the latest fair value trim as a reminder that execution and growth expectations for Trulieve Cannabis still carry meaningful risk, even with a higher revenue and margin outlook built into the model.TRUL: Retail Expansion And Rescheduling Progress Will Support Higher Future Earnings Multiples
Analysts have made a small upward adjustment to their Trulieve Cannabis fair value estimate, reflecting only modest tweaks to long term profit margin and future P/E assumptions rather than a wholesale shift in their outlook. Analyst Commentary Recent Street research around comparable business services and data providers offers some useful clues for how analysts may be thinking about Trulieve Cannabis valuation and execution, even though the coverage is focused on different companies.TRUL: Retail Expansion Into New States Will Drive Future Earnings Multiples
Analysts nudged their price target on Trulieve Cannabis slightly higher, by about $0.16, as they factor in stronger multi year revenue growth, improving profit margins, and a more reasonable future earnings multiple, while still maintaining a similar discount rate framework. Analyst Commentary Recent commentary around Trulieve Cannabis reflects a more constructive, yet still measured, stance as analysts incorporate updated assumptions for growth, profitability, and regulatory visibility into their valuation work.Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 55% But Its Business Is Yet to Catch Up
Dec 22TRUL: Future Execution And Regulatory Shifts Will Shape Risk-Reward Balance
Analysts have lifted their price target on Trulieve Cannabis to approximately $14.90 from about $11.01, citing stronger expected revenue growth, improved profit margins, and a more reasonable future P/E multiple despite a slightly higher discount rate. Analyst Commentary Bearish analysts acknowledge Trulieve Cannabis's improved outlook but remain wary of execution and valuation risks in a still evolving regulatory and competitive landscape.TRUL: Retail Expansion And New Markets Will Support Share Price Momentum
The analyst price target for Trulieve Cannabis has decreased slightly from $19.16 to $18.87. Analysts cite modest adjustments to profit margin expectations and valuation metrics as reasons for the change.Trulieve Cannabis Corp. (CSE:TRUL) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
Nov 08Some Trulieve Cannabis Corp. (CSE:TRUL) Shareholders Look For Exit As Shares Take 29% Pounding
Nov 07TRUL: Future Market Expansion Will Drive Share Price Momentum
Trulieve Cannabis’s analyst price target has been raised from $17.89 to $19.16. Analysts cite improved revenue growth projections and stable profit margins as key drivers for the upward revision.We Think Trulieve Cannabis (CSE:TRUL) Is Taking Some Risk With Its Debt
Oct 27Trulieve Cannabis Corp.'s (CSE:TRUL) Shares Climb 97% But Its Business Is Yet to Catch Up
Aug 29Revenues Not Telling The Story For Trulieve Cannabis Corp. (CSE:TRUL) After Shares Rise 28%
Jul 11Does Trulieve Cannabis (CSE:TRUL) Have A Healthy Balance Sheet?
Jun 12
Adult-Use Cannabis Expansion In Florida And Pennsylvania Will Broaden Markets
Strategic retail expansion and new market entry in key states could significantly boost revenue and market share by tapping into adult-use markets.Here's Why Trulieve Cannabis (CSE:TRUL) Has A Meaningful Debt Burden
Jan 10More Unpleasant Surprises Could Be In Store For Trulieve Cannabis Corp.'s (CSE:TRUL) Shares After Tumbling 56%
Dec 05Are Investors Undervaluing Trulieve Cannabis Corp. (CSE:TRUL) By 47%?
Sep 04Trulieve Cannabis Corp.'s (CSE:TRUL) 28% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 15Trulieve Cannabis Corp.'s (CSE:TRUL) CEO Will Probably Struggle To See A Pay Rise This Year
Jun 06Are Investors Undervaluing Trulieve Cannabis Corp. (CSE:TRUL) By 38%?
May 01Revenues Not Telling The Story For Trulieve Cannabis Corp. (CSE:TRUL) After Shares Rise 26%
Mar 31Is Trulieve Cannabis (CSE:TRUL) A Risky Investment?
Feb 15There's Reason For Concern Over Trulieve Cannabis Corp.'s (CSE:TRUL) Massive 29% Price Jump
Jan 16Calculating The Intrinsic Value Of Trulieve Cannabis Corp. (CSE:TRUL)
Mar 06Shareholder Returns
| TRUL | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 10.8% | 3.9% | 0.1% |
| 1Y | 103.9% | 44.9% | 35.1% |
Return vs Industry: TRUL exceeded the Canadian Pharmaceuticals industry which returned 44.9% over the past year.
Return vs Market: TRUL exceeded the Canadian Market which returned 35.1% over the past year.
Price Volatility
| TRUL volatility | |
|---|---|
| TRUL Average Weekly Movement | 13.3% |
| Pharmaceuticals Industry Average Movement | 12.1% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: TRUL has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: TRUL's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1940 | 5,000 | Kim Rivers | www.trulieve.com |
Trulieve Cannabis Corp. operates as a cannabis retailer in the United States. The company cultivates, processes, and manufactures cannabis products and distributes its products to its dispensaries, as well as through home delivery. It sells flowers, edibles, vapes, oral, topical, concentrates, and accessories under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, and Roll One brands.
Trulieve Cannabis Corp. Fundamentals Summary
| TRUL fundamental statistics | |
|---|---|
| Market cap | CA$2.54b |
| Earnings (TTM) | -CA$150.56m |
| Revenue (TTM) | CA$1.61b |
1.6x
P/S Ratio-16.8x
P/E RatioIs TRUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TRUL income statement (TTM) | |
|---|---|
| Revenue | US$1.18b |
| Cost of Revenue | US$470.01m |
| Gross Profit | US$711.17m |
| Other Expenses | US$821.94m |
| Earnings | -US$110.77m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 60.21% |
| Net Profit Margin | -9.38% |
| Debt/Equity Ratio | 20.4% |
How did TRUL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 01:52 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Trulieve Cannabis Corp. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |